Medscape reviews emerging trial signals across pancreatic, gastric, and colorectal cancers from ASCO GI 2026, including new precision strategies and immunotherapy directions for difficult tumor types.
ASCO GI: Practice-Changing Signals Across Pancreatic, Gastric, and Colorectal Cancers
Practice-changing signals are emerging from the 2026 ASCO GI Symposium
potential of immunotherapy in "immune desert" tumors
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare